Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling-Reference-Cited by-同舟云学术

Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling

Published:2023-04-03 Issue:15 Volume:8 Page:13741-13753
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Gao Dongmei¹,Wang Guopeng²,Wu Honghai³,Wu JinHua⁴^ORCID,Zhao Xiaoang⁵

Affiliation:

1. Department of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang 050082, China

2. Zhongcai Health (Beijing) Biological Technology Development Co., Ltd., Beijing 101500, China

3. Department of Clinical Pharmacy, Bethune International Peace Hospital, Shijiazhuang 050082, China

4. Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China

5. Institute of Chinese Material Medica China Academy of Chinese Medical Sciences, Beijing 100700, China

Funder

China Academy of Chinese Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.2c07967

Reference58 articles.

1. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

2. National Institutes of Health (NIH). https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=7b7cc194-29e4-4484-a364-a1ac7d7d6cf5.

3. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes

4. Food and Drug Administration (FDA). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf.

5. METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. İLAÇLARDA SANAL BİYOEŞDEĞERLİK UYGULAMALARI;Ankara Universitesi Eczacilik Fakultesi Dergisi;2024-06-14

2. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03

3. Impact of CYP3A4 rs2242480 polymorphisms on Imatinib HPLC determined trough concentration and response in Chronic Myeloid Leukaemia in Pakistani patients;F1000Research;2024-04-22

4. Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions;CPT: Pharmacometrics & Systems Pharmacology;2024-03-14

5. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach;Frontiers in Pharmacology;2024-03-04